Eupalinolide A attenuates trauma-induced heterotopic ossification of tendon in mice by promoting YAP degradation through TOLLIP-mediated selective autophagy

• Published in: Phytomedicine (Stuttgart) 2024-12, Vol.135, p.156163, Article 156163
• Main Authors: Jiang, Huaji, Ding, Yan, Wu, Yongfu, Xie, Yingchao, Tian, Qinyu, Yang, Cheng, Liu, Yakui, Lin, Xuemei, Song, Bin, He, Hebei, Wan, Li, Tian, Xinggui
• Format: Article
• Language: English
• Subjects: Adaptor Proteins, Signal Transducing - metabolism; Animals; Autophagy; Autophagy - drug effects; bone formation; Cell Differentiation - drug effects; Disease Models, Animal; Eupalinolide A; Heterotopic ossification; Intracellular Signaling Peptides and Proteins - metabolism; Male; Mice; Mice, Inbred C57BL; Ossification, Heterotopic - drug therapy; Osteogenesis - drug effects; Signal Transduction - drug effects; Stem Cells - drug effects; Tendon; Tendon Injuries - drug therapy; Tendons - drug effects; therapeutics; Transcription Factors - metabolism; ubiquitin-protein ligase; Ubiquitin-Protein Ligases - metabolism; Ubiquitination; YAP; YAP-Signaling Proteins
• ISSN: 0944-7113; 1618-095X; 1618-095X
• DOI: 10.1016/j.phymed.2024.156163

Inhibiting the aberrant osteogenic differentiation of tendon-derived stem cells (TDSCs) is an effective strategy for treating traumatic heterotopic ossification (HO) in tendons. This study aimed to investigate whether eupalinolide A (EA) could prevent tendon HO progression by suppressing the osteogenic differentiation of TDSCs. The effects of EA on osteogenic differentiation and key signaling pathways in TDSCs were examined in vitro to assess its therapeutic potential and elucidate the underlying molecular mechanisms. Furthermore, the therapeutic efficacy of EA was evaluated in a mouse model of trauma-induced tendon HO via local injection therapy. EA significantly inhibited the osteogenic differentiation of TDSCs by targeting YAP in vitro. Specifically, EA facilitated the recruitment of E3 ubiquitin ligase HECW1, which mediated K27-linked polyubiquitination of YAP, leading to its degradation via the TOLLIP-mediated selective autophagy pathway. In vivo, EA mitigated trauma-induced tendon HO by inhibiting the YAP pathway. EA could be a potential therapeutic agent for treating traumatic tendon HO. The therapeutic target HECW1 involved in YAP degradation via autophagy presents a new therapeutic avenue to attenuate the progression of traumatic tendon HO. [Display omitted]